Table 5.
Predicted half-lives of the novel SARS-CoV-2-derived, most immunogenic in-silico-identified epitopes in complex with the allotypes shown in Table 2. Secondary structures, localization within SARS-CoV-2, GRAVY scores and known mutations in the epitopes.
| Epitopes | Allotype | Epitope Mutation | Half-Life (in Hours) | Localization | GRAVY Score |
|---|---|---|---|---|---|
| 738DTDFVNEFY746 | A*01:01 | E744D T739I |
2.84 | intravirion | −0.689 |
| 1505LVAEWFLAY1513 | A*29:02 | No | 3.64 | transmembrane | 1.389 |
| 289SHFAIGLAL297 | B*39:01 | H290Y A296S L297F |
2.02 | intravirion | 1.567 |
| 1507AEWFLAYIL1515 | B*40:01 | No | 2.04 | transmembrane | 1.422 |
| 1505LVAEWFLAY1513 | B*35:01 | No | 1.69 | transmembrane | 1.389 |
| 1507AEWFLAYIL1515 | B*40:02 | No | 3.81 | transmembrane | 1.422 |
| 217AMDEFIERY225 | A*01:01 | A217V F221L R224Q |
1.26 | intravirion | −0.589 |
| 1505LVAEWFLAY1513 | B*15:01 | No | 7.51 | transmembrane | 1.389 |
| 1505LVAEWFLAY1513 | A*26:01 | No | 1.33 | transmembrane | 1.389 |